Key highlights
- Boehringer Ingelheim and Simcere partner to develop SIM0709 for IBD.
- SIM0709 is a TL1A/IL23p19 bispecific antibody.
- SIM0709 targets TL1A and IL-23 pathways in IBD.
- Pre-clinical studies show SIM0709's superior efficacy.
Partnership Overview
Boehringer Ingelheim and Simcere Pharmaceutical Group have entered a license and collaboration agreement to develop SIM0709, a pre-clinical bispecific antibody, for treating inflammatory bowel disease (IBD).
Unmet Needs in IBD
IBD affects over three million people globally, leading to frequent hospitalizations and surgeries. Current treatments do not fully address these complications, highlighting a significant unmet need.
SIM0709 Mechanism
SIM0709 is a long-acting humanized bispecific antibody developed by Simcere. It targets TL1A and IL-23, blocking two key pathways involved in IBD onset and progression.
Pre-Clinical Efficacy
In vitro and in vivo studies show SIM0709's superior synergistic efficacy, outperforming the combination of two corresponding monotherapies.
